Indaptus Therapeutics Debt-to-Equity Ratio Growth & History (INDP)
Indaptus Therapeutics's debt-to-equity ratio was 0.00 for fiscal 2025.
View full Indaptus Therapeutics company overviewIndaptus Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.00 | −0.02 | — |
| 2024 | 2024-12-31 | 0.02 | 0.01 | +47.19% |
| 2023 | 2023-12-31 | 0.01 | 0.01 | +343.54% |
| 2022 | 2022-12-31 | 0.00 | −0.00 | −30.71% |
| 2021 | 2021-12-31 | 0.00 | — | — |
Indaptus Therapeutics quarterly debt-to-equity ratio
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 0.00 | −0.02 | — |
| Q3 2025 | 2025-09-30 | 0.00 | −0.02 | −89.52% |
| Q1 2025 | 2025-03-31 | 0.02 | 0.00 | +29.94% |
| Q4 2024 | 2024-12-31 | 0.02 | 0.01 | +47.19% |
| Q3 2024 | 2024-09-30 | 0.02 | 0.01 | +40.56% |
| Q2 2024 | 2024-06-30 | 0.02 | 0.01 | +82.42% |
| Q1 2024 | 2024-03-31 | 0.02 | 0.01 | +46.54% |
| Q4 2023 | 2023-12-31 | 0.01 | 0.01 | +343.54% |
| Q3 2023 | 2023-09-30 | 0.01 | 0.01 | +240.63% |
| Q2 2023 | 2023-06-30 | 0.01 | 0.01 | +181.06% |
| Q1 2023 | 2023-03-31 | 0.01 | 0.01 | +152.12% |
| Q4 2022 | 2022-12-31 | 0.00 | −0.00 | −30.71% |
| Q3 2022 | 2022-09-30 | 0.00 | — | — |
| Q2 2022 | 2022-06-30 | 0.00 | — | — |
| Q1 2022 | 2022-03-31 | 0.00 | — | — |
| Q4 2021 | 2021-12-31 | 0.00 | — | — |
Indaptus Therapeutics debt-to-equity ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, Indaptus Therapeutics's debt-to-equity ratio decreased from 0.00 to 0.00, a change of −0.00. The latest reported quarter, Q4 2025, shows 0.00.
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Indaptus Therapeutics source filings ↗